FDA Inspection 1012256 — Mark L. Brantly, M.D.
The FDA completed an inspection of Mark L. Brantly, M.D. on April 14, 2017 in Gainesville, FL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 14, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Gainesville, FL (United States)
Additional Details
Clinical Investigator (CI)